What is the real-world economic burden associated with complications from hematopoietic cell transplantation? What prognostic factors for posttransplantation outcomes among patients with chronic myelomonocytic leukemia are significant predictors of survival? Answer these and more in our latest quiz.
What is the real-world economic burden associated with complications from hematopoietic cell transplantation? What prognostic factors for posttransplantation outcomes among patients with chronic myelomonocytic leukemia are significant predictors of survival? Test your knowledge in our latest quiz.
B. > 55
Patients in the study underwent autologous hematopoietic transplantation with carmustine, etoposide, cytarabine, and melphalan conditioning therapy. At a median follow-up of 80 months, progression-free survival was similar between both age groups. Patients older than 55 years of age, however, had a significantly poorer overall survival that was attributed to a higher rate of second malignancies.
A. Allogeneic HCT recipients with complications had a lower survival rate than those without complications
Allogeneic HCT recipients with complications experienced no significant difference in mortality rate or in probability of surviving compared with those without complications, according to the study, which included over 2,500 patients. A higher mortality rate was, however, observed among those with autologous HCT and complications.
B. Age, sibling donor HCT, use of PBSCs
According to the National Cancer Institute’s PDQ on Childhood Cancers, chronic GVHD occurs in 20% to 45% of children after an unrelated donor HCT, compared with 15% to 30% of those after sibling donor HCT, with higher risk associated with use of PBSCs than with cord blood. A patient’s age, conditioning regimen, and history of acute GVHD are also risk factors for developing chronic GVHD.
D. All of the above
The study reported that patients with intermediate-2/high risk CMML-specific prognostic scoring system (CPSS) scores who relapsed after HCT had a nearly twofold increased risk of death compared with patients with low/intermediate-1 CPSS scores.
The approval is intended for patients with GVHD who have failed on one or more lines of prior systemic therapy. Ibrutinib is the first drug to be approved for the treatment of GVHD.